nilotinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1932 641571-10-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nilotinib hydrochloride hydrate
  • nilotinib
  • tasigna
  • nilotinib hydrochloride monohydrate
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.
  • Molecular weight: 529.53
  • Formula: C28H22F3N7O
  • CLOGP: 5.69
  • LIPINSKI: 2
  • HAC: 8
  • HDO: 2
  • TPSA: 97.62
  • ALOGS: -5.42
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.58 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 29, 2007 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rash 820.65 29.12 367 4127 59191 2294400
Electrocardiogram QT prolonged 685.43 29.12 192 4302 7622 2345969
Peripheral arterial occlusive disease 548.37 29.12 100 4394 489 2353102
Chronic myeloid leukaemia 535.90 29.12 98 4396 488 2353103
Cytogenetic analysis abnormal 453.90 29.12 67 4427 41 2353550
Nausea 426.74 29.12 297 4197 111892 2241699
Fatigue 407.29 29.12 260 4234 84613 2268978
Pruritus 403.16 29.12 205 4289 43135 2310456
Anaemia 362.82 29.12 178 4316 34614 2318977
Pleural effusion 358.24 29.12 129 4365 11539 2342052
Death 354.61 29.12 235 4259 81233 2272358
Headache 345.79 29.12 230 4264 79949 2273642
Thrombocytopenia 342.93 29.12 143 4351 18988 2334603
Second primary malignancy 326.94 29.12 71 4423 935 2352656
Lipase increased 311.01 29.12 73 4421 1389 2352202
Dyspnoea 296.72 29.12 208 4286 78525 2275066
Myocardial infarction 293.85 29.12 128 4366 18885 2334706
Pyrexia 285.19 29.12 176 4318 53532 2300059
Platelet count decreased 279.11 29.12 117 4377 15696 2337895
Alopecia 272.81 29.12 127 4367 21874 2331717
Pain in extremity 271.41 29.12 157 4337 42383 2311208
Bone pain 259.21 29.12 95 4399 8901 2344690
Blood bilirubin increased 257.72 29.12 83 4411 5262 2348329
Malignant neoplasm progression 248.85 29.12 100 4394 12028 2341563
Blast crisis in myelogenous leukaemia 243.25 29.12 41 4453 112 2353479
Vomiting 234.58 29.12 174 4320 71428 2282163
Abdominal pain upper 229.51 29.12 113 4381 21987 2331604
Myalgia 220.76 29.12 112 4382 23221 2330370
Chest pain 217.64 29.12 118 4376 28019 2325572
Abdominal pain 203.43 29.12 121 4373 34253 2319338
Pancytopenia 202.74 29.12 85 4409 11367 2342224
Arthralgia 200.43 29.12 142 4352 54143 2299448
Intermittent claudication 188.45 29.12 37 4457 283 2353308
Diarrhoea 187.96 29.12 163 4331 83401 2270190
Asthenia 187.72 29.12 129 4365 46797 2306794
Cerebrovascular accident 185.32 29.12 95 4399 20091 2333500
Pancreatitis 184.39 29.12 72 4422 8007 2345584
Chronic myeloid leukaemia transformation 180.72 29.12 27 4467 20 2353571
Blood glucose increased 174.24 29.12 78 4416 12212 2341379
Drug resistance 173.78 29.12 52 4442 2572 2351019
Pain 172.93 29.12 137 4357 61720 2291871
White blood cell count increased 164.75 29.12 64 4430 7014 2346577
Angina pectoris 164.22 29.12 55 4439 3932 2349659
Pneumonia 161.38 29.12 120 4374 49176 2304415
Palpitations 155.46 29.12 79 4415 16377 2337214
Alanine aminotransferase increased 152.18 29.12 74 4420 13958 2339633
Atrial fibrillation 150.49 29.12 73 4421 13695 2339896
Peripheral artery stenosis 146.61 29.12 26 4468 104 2353487
Muscle spasms 143.43 29.12 82 4412 21484 2332107
Back pain 143.07 29.12 94 4400 31565 2322026
Acute myocardial infarction 140.32 29.12 52 4442 5003 2348588
Maternal exposure during pregnancy 139.33 29.12 71 4423 14792 2338799
Arteriosclerosis 136.46 29.12 38 4456 1450 2352141
Peripheral vascular disorder 136.39 29.12 34 4460 837 2352754
Pericardial effusion 132.80 29.12 47 4447 3962 2349629
Dyspepsia 131.59 29.12 60 4434 9784 2343807
Haemoglobin decreased 131.45 29.12 73 4421 18078 2335513
Constipation 127.32 29.12 76 4418 21553 2332038
Platelet count increased 125.35 29.12 39 4455 2198 2351393
Dizziness 120.60 29.12 109 4385 58556 2295035
Dry skin 116.33 29.12 49 4445 6603 2346988
Hypertension 115.71 29.12 78 4416 27283 2326308
Hyperbilirubinaemia 112.57 29.12 33 4461 1516 2352075
Bone marrow failure 109.94 29.12 45 4449 5641 2347950
Normal newborn 109.20 29.12 31 4463 1269 2352322
Diabetes mellitus 107.49 29.12 48 4446 7447 2346144
Decreased appetite 107.20 29.12 76 4418 28815 2324776
Neutropenia 107.12 29.12 68 4426 21480 2332111
Cough 106.75 29.12 80 4414 33037 2320554
Aspartate aminotransferase increased 105.95 29.12 56 4438 12556 2341035
Malaise 105.86 29.12 99 4395 55486 2298105
White blood cell count decreased 101.98 29.12 62 4432 18146 2335445
Drug intolerance 101.53 29.12 56 4438 13661 2339930
Weight decreased 101.49 29.12 73 4421 28298 2325293
Hepatic enzyme increased 98.16 29.12 49 4445 9753 2343838
Coronary artery disease 98.03 29.12 42 4452 5897 2347694
Skin disorder 95.79 29.12 36 4458 3595 2349996
Abdominal distension 95.36 29.12 49 4445 10362 2343229
Therapeutic response decreased 93.42 29.12 43 4451 7152 2346439
Hyperglycaemia 92.17 29.12 38 4456 4847 2348744
Cardiac failure 91.21 29.12 50 4444 12044 2341547
Gamma-glutamyltransferase increased 90.70 29.12 39 4455 5523 2348068
Carotid artery stenosis 89.98 29.12 24 4470 776 2352815
Splenomegaly 86.71 29.12 27 4467 1524 2352067
Haematotoxicity 85.40 29.12 25 4469 1142 2352449
Leukopenia 84.83 29.12 45 4449 10151 2343440
Myocardial ischaemia 84.42 29.12 29 4465 2233 2351358
Neoplasm malignant 83.99 29.12 36 4458 5057 2348534
Weight increased 78.74 29.12 57 4437 22280 2331311
Hypercholesterolaemia 77.35 29.12 25 4469 1593 2351998
Nasopharyngitis 77.10 29.12 56 4438 22000 2331591
Hepatic function abnormal 74.69 29.12 35 4459 6057 2347534
Acute lymphocytic leukaemia recurrent 73.56 29.12 16 4478 211 2353380
Oedema peripheral 73.37 29.12 56 4438 23707 2329884
Amylase increased 72.70 29.12 22 4472 1127 2352464
Chest discomfort 72.32 29.12 46 4448 14549 2339042
Blood lactate dehydrogenase increased 72.22 29.12 29 4465 3455 2350136
Cytopenia 71.13 29.12 21 4473 988 2352603
Concomitant disease aggravated 70.98 29.12 21 4473 995 2352596
Fluid retention 69.85 29.12 35 4459 7011 2346580
Gait disturbance 69.31 29.12 53 4441 22492 2331099
Jaundice 68.62 29.12 32 4462 5476 2348115
Thrombocytosis 68.45 29.12 20 4474 907 2352684
Oedema 68.24 29.12 39 4455 10164 2343427
Acute coronary syndrome 65.85 29.12 22 4472 1555 2352036
Arterial occlusive disease 65.74 29.12 18 4476 643 2352948
Drug ineffective 64.77 29.12 104 4390 101520 2252071
Leukocytosis 64.68 29.12 27 4467 3549 2350042
Transaminases increased 64.53 29.12 29 4465 4558 2349033
Influenza 64.53 29.12 41 4453 12937 2340654
Gastrooesophageal reflux disease 64.16 29.12 36 4458 9059 2344532
General physical health deterioration 63.74 29.12 42 4452 14097 2339494
Peripheral ischaemia 63.61 29.12 18 4476 727 2352864
Labelled drug-food interaction medication error 62.16 29.12 10 4484 18 2353573
Arterial disorder 61.10 29.12 14 4480 237 2353354
Insomnia 58.93 29.12 51 4443 25736 2327855
Philadelphia chromosome positive 57.65 29.12 10 4484 34 2353557
Transient ischaemic attack 57.21 29.12 29 4465 5949 2347642
Cerebral infarction 55.95 29.12 26 4468 4411 2349180
Blood cholesterol increased 54.80 29.12 27 4467 5214 2348377
Blood alkaline phosphatase increased 54.73 29.12 29 4465 6516 2347075
Basophil count increased 54.40 29.12 11 4483 99 2353492
Chronic myeloid leukaemia recurrent 54.08 29.12 9 4485 22 2353569
Gastrointestinal stromal tumour 53.95 29.12 13 4481 276 2353315
Musculoskeletal pain 53.29 29.12 34 4460 10796 2342795
Liver disorder 52.45 29.12 28 4466 6386 2347205
Hypoaesthesia 52.39 29.12 43 4451 20172 2333419
Blood creatine phosphokinase increased 52.33 29.12 26 4468 5110 2348481
Incorrect dose administered 51.62 29.12 32 4462 9663 2343928
Hyperhidrosis 51.24 29.12 38 4456 15384 2338207
Dyslipidaemia 50.26 29.12 15 4479 732 2352859
Vertigo 50.03 29.12 31 4463 9353 2344238
Anxiety 49.49 29.12 49 4445 29310 2324281
Abdominal discomfort 49.19 29.12 39 4455 17417 2336174
Productive cough 48.55 29.12 25 4469 5296 2348295
Syncope 48.19 29.12 38 4456 16837 2336754
Erythema 48.08 29.12 45 4449 25114 2328477
Sensory loss 47.92 29.12 16 4478 1128 2352463
Peripheral artery occlusion 47.52 29.12 11 4483 195 2353396
Acute myeloid leukaemia 47.46 29.12 20 4474 2690 2350901
Exposure via father 46.61 29.12 11 4483 213 2353378
Therapy non-responder 46.34 29.12 28 4466 8076 2345515
Dysphagia 45.81 29.12 33 4461 12772 2340819
Muscular weakness 45.70 29.12 35 4459 14862 2338729
Feeling abnormal 44.71 29.12 42 4452 23539 2330052
Coronary artery stenosis 44.66 29.12 14 4480 807 2352784
Fall 44.20 29.12 58 4436 47041 2306550
Infection 43.90 29.12 37 4457 17992 2335599
Hypothyroidism 43.75 29.12 22 4472 4435 2349156
Concomitant disease progression 43.71 29.12 12 4482 433 2353158
Gangrene 43.53 29.12 13 4481 636 2352955
Liver function test abnormal 43.14 29.12 26 4468 7464 2346127
Rash pruritic 42.99 29.12 26 4468 7509 2346082
Hepatotoxicity 42.65 29.12 20 4474 3461 2350130
Food interaction 42.25 29.12 10 4484 196 2353395
Blood creatinine increased 41.97 29.12 29 4465 10504 2343087
Sepsis 41.07 29.12 36 4458 18452 2335139
Pulmonary oedema 40.97 29.12 25 4469 7338 2346253
Angiopathy 40.88 29.12 13 4481 785 2352806
Chromaturia 40.61 29.12 18 4476 2735 2350856
Pain of skin 40.52 29.12 15 4479 1433 2352158
Ischaemic stroke 40.03 29.12 19 4475 3378 2350213
Neoplasm progression 39.92 29.12 21 4473 4647 2348944
Oropharyngeal pain 39.64 29.12 29 4465 11489 2342102
Cardiac disorder 39.54 29.12 25 4469 7808 2345783
Renal failure 38.97 29.12 34 4460 17315 2336276
Dyspnoea exertional 38.59 29.12 22 4472 5698 2347893
Blast cell crisis 38.35 29.12 7 4487 34 2353557
Neck pain 37.45 29.12 24 4470 7673 2345918
Haemorrhage 36.20 29.12 27 4467 11012 2342579
Xanthelasma 35.96 29.12 6 4488 15 2353576
Red blood cell count decreased 35.93 29.12 19 4475 4247 2349344
Vision blurred 35.49 29.12 30 4464 14638 2338953
Therapy cessation 35.10 29.12 20 4474 5173 2348418
Cardiac failure congestive 35.05 29.12 31 4463 16070 2337521
Cardiac arrest 35.03 29.12 30 4464 14900 2338691
Hypokalaemia 34.80 29.12 26 4468 10628 2342963
Ear pain 34.31 29.12 16 4478 2733 2350858
Gastrointestinal disorder 34.23 29.12 24 4470 8893 2344698
Facial paralysis 33.08 29.12 15 4479 2404 2351187
Breast cancer 32.88 29.12 24 4470 9471 2344120
Acne 32.12 29.12 16 4478 3160 2350431
Exposure via partner 32.06 29.12 7 4487 94 2353497
Paraesthesia 32.00 29.12 34 4460 22054 2331537
Pancreatitis acute 32.00 29.12 17 4477 3836 2349755
Chills 31.98 29.12 29 4465 15523 2338068
Gastritis 31.92 29.12 18 4476 4563 2349028
Dysarthria 31.52 29.12 20 4474 6282 2347309
Skin lesion 31.30 29.12 17 4477 4008 2349583
Pancreatic enzymes increased 31.22 29.12 8 4486 220 2353371
Granuloma skin 30.68 29.12 7 4487 116 2353475
Contusion 30.58 29.12 26 4468 12784 2340807
Leukaemia recurrent 30.43 29.12 8 4486 244 2353347
Memory impairment 30.38 29.12 26 4468 12897 2340694
Cardiomegaly 30.07 29.12 14 4480 2382 2351209
Left ventricular hypertrophy 30.00 29.12 10 4484 701 2352890
Supraventricular extrasystoles 29.66 29.12 10 4484 726 2352865
Pallor 29.64 29.12 16 4478 3726 2349865
Mitral valve incompetence 29.24 29.12 14 4480 2536 2351055
Neutrophil count increased 29.22 29.12 13 4481 1992 2351599
C-reactive protein increased 29.18 29.12 19 4475 6236 2347355

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 769.07 30.89 226 5111 5319 1736125
Rash 650.80 30.89 339 4998 38354 1703090
Death 634.13 30.89 445 4892 86998 1654446
Peripheral arterial occlusive disease 544.24 30.89 117 5220 691 1740753
Chronic myeloid leukaemia 538.15 30.89 113 5224 585 1740859
Second primary malignancy 496.59 30.89 114 5223 945 1740499
Pleural effusion 494.75 30.89 193 5144 10917 1730527
Fatigue 467.27 30.89 301 5036 50480 1690964
Myocardial infarction 437.58 30.89 232 5105 26942 1714502
Angina pectoris 427.04 30.89 141 5196 4877 1736567
Blast crisis in myelogenous leukaemia 397.69 30.89 73 5264 153 1741291
Dyspnoea 348.44 30.89 254 5083 51805 1689639
Chest pain 345.50 30.89 179 5158 19735 1721709
Intermittent claudication 345.20 30.89 72 5265 357 1741087
Thrombocytopenia 323.30 30.89 175 5162 21074 1720370
Platelet count decreased 302.19 30.89 154 5183 16369 1725075
Blood bilirubin increased 286.80 30.89 111 5226 6099 1735345
Cytogenetic analysis abnormal 284.61 30.89 47 5290 32 1741412
Pruritus 281.92 30.89 165 5172 23057 1718387
Lipase increased 281.57 30.89 79 5258 1545 1739899
Pyrexia 253.59 30.89 201 5136 46199 1695245
Pain in extremity 252.77 30.89 142 5195 18330 1723114
Abdominal pain upper 249.99 30.89 119 5218 10882 1730562
Coronary artery disease 249.97 30.89 115 5222 9731 1731713
Anaemia 248.22 30.89 166 5171 29291 1712153
Malignant neoplasm progression 247.20 30.89 128 5209 14030 1727414
Abdominal pain 245.77 30.89 147 5190 21343 1720101
Pancreatitis 244.03 30.89 103 5234 7084 1734360
Headache 227.32 30.89 167 5170 34209 1707235
Coronary artery stenosis 216.35 30.89 64 5273 1518 1739926
Drug resistance 208.86 30.89 74 5263 3156 1738288
Nausea 207.86 30.89 187 5150 51009 1690435
Myalgia 199.56 30.89 115 5222 15543 1725901
Atrial fibrillation 189.93 30.89 110 5227 15001 1726443
White blood cell count increased 187.29 30.89 86 5251 7226 1734218
Peripheral vascular disorder 181.03 30.89 48 5289 750 1740694
Blood glucose increased 173.99 30.89 92 5245 10492 1730952
Haemoglobin decreased 167.16 30.89 106 5231 17008 1724436
Acute myocardial infarction 165.23 30.89 83 5254 8504 1732940
Arthralgia 163.93 30.89 118 5219 23326 1718118
Cerebrovascular accident 162.98 30.89 106 5231 17760 1723684
Hyperglycaemia 148.87 30.89 66 5271 5099 1736345
Peripheral artery stenosis 147.22 30.89 30 5307 129 1741315
Pneumonia 145.74 30.89 147 5190 46035 1695409
Myocardial ischaemia 143.39 30.89 56 5281 3137 1738307
Cough 139.56 30.89 99 5238 19098 1722346
Muscle spasms 139.02 30.89 82 5255 11539 1729905
Concomitant disease aggravated 136.67 30.89 38 5299 715 1740729
Cardiac failure 135.43 30.89 83 5254 12519 1728925
Chronic myeloid leukaemia transformation 134.59 30.89 24 5313 39 1741405
Pain 133.33 30.89 110 5227 26547 1714897
Chest discomfort 132.63 30.89 68 5269 7263 1734181
Drug intolerance 129.64 30.89 63 5274 5999 1735445
Bone pain 126.79 30.89 52 5285 3310 1738134
Weight decreased 124.54 30.89 99 5238 22654 1718790
Pancytopenia 122.51 30.89 75 5262 11282 1730162
Diabetes mellitus 121.84 30.89 63 5274 6845 1734599
Arterial disorder 121.75 30.89 28 5309 232 1741212
Asthenia 121.54 30.89 117 5220 34553 1706891
Malaise 121.43 30.89 109 5228 29456 1711988
Alanine aminotransferase increased 119.62 30.89 76 5261 12202 1729242
Hypertension 118.08 30.89 90 5247 19358 1722086
White blood cell count decreased 117.29 30.89 77 5260 13072 1728372
Back pain 114.53 30.89 83 5254 16530 1724914
Vomiting 113.49 30.89 118 5219 38197 1703247
Dizziness 113.02 30.89 112 5225 34249 1707195
Splenomegaly 112.47 30.89 42 5295 2078 1739366
Diarrhoea 110.49 30.89 137 5200 53715 1687729
Carotid artery stenosis 107.53 30.89 32 5305 773 1740671
Arteriosclerosis 106.85 30.89 39 5298 1808 1739636
Cerebral infarction 104.97 30.89 52 5285 5157 1736287
Acute coronary syndrome 104.63 30.89 41 5296 2314 1739130
Chronic myeloid leukaemia recurrent 99.92 30.89 18 5319 32 1741412
Hypercholesterolaemia 98.60 30.89 33 5304 1179 1740265
Decreased appetite 97.90 30.89 88 5249 23783 1717661
Gamma-glutamyltransferase increased 97.14 30.89 49 5288 5049 1736395
Constipation 92.25 30.89 70 5267 14930 1726514
Neoplasm malignant 89.45 30.89 44 5293 4295 1737149
Peripheral artery occlusion 87.49 30.89 21 5316 213 1741231
Pericardial effusion 87.08 30.89 40 5297 3350 1738094
Arrhythmia 86.74 30.89 48 5289 5968 1735476
Hypoaesthesia 81.38 30.89 55 5282 9780 1731664
Palpitations 81.17 30.89 48 5289 6766 1734678
Angina unstable 80.05 30.89 33 5304 2125 1739319
Oedema peripheral 79.31 30.89 65 5272 15485 1725959
Aspartate aminotransferase increased 79.24 30.89 56 5281 10700 1730744
Concomitant disease progression 79.17 30.89 23 5314 509 1740935
Blood creatinine increased 76.85 30.89 61 5276 13885 1727559
Leukocytosis 76.33 30.89 37 5300 3496 1737948
Arterial stenosis 75.22 30.89 18 5319 180 1741264
Oedema 75.14 30.89 46 5291 6902 1734542
Infection 74.46 30.89 57 5280 12303 1729141
Alopecia 71.26 30.89 36 5301 3717 1737727
Amylase increased 70.78 30.89 26 5311 1226 1740218
Blood creatine phosphokinase increased 69.63 30.89 48 5289 8808 1732636
Musculoskeletal pain 69.09 30.89 39 5298 5035 1736409
Hyperlipidaemia 69.07 30.89 30 5307 2199 1739245
Peripheral ischaemia 68.09 30.89 23 5314 845 1740599
Mitral valve incompetence 66.32 30.89 28 5309 1914 1739530
Therapeutic response decreased 66.16 30.89 39 5298 5461 1735983
Abdominal distension 65.46 30.89 41 5296 6403 1735041
Dyspnoea exertional 64.94 30.89 35 5302 4126 1737318
Dry skin 62.95 30.89 33 5304 3679 1737765
Bone marrow failure 62.88 30.89 37 5300 5163 1736281
Gastrointestinal stromal tumour 62.85 30.89 18 5319 378 1741066
Incorrect dose administered 62.62 30.89 42 5295 7367 1734077
Neutropenia 62.61 30.89 61 5276 18199 1723245
Nasopharyngitis 62.12 30.89 47 5290 9963 1731481
Renal failure 61.51 30.89 63 5274 19954 1721490
Acne 61.51 30.89 26 5311 1782 1739662
Drug ineffective 61.15 30.89 114 5223 63687 1677757
Coronary artery occlusion 58.21 30.89 26 5311 2037 1739407
Hyperuricaemia 57.78 30.89 21 5316 960 1740484
Erythema 57.46 30.89 52 5285 14136 1727308
Hepatic function abnormal 57.15 30.89 39 5298 7035 1734409
Gait disturbance 56.41 30.89 49 5288 12621 1728823
Gene mutation identification test positive 55.68 30.89 12 5325 71 1741373
Abdominal discomfort 54.93 30.89 42 5295 9039 1732405
Gangrene 54.29 30.89 19 5318 777 1740667
Liver disorder 52.60 30.89 34 5303 5602 1735842
Acute lymphocytic leukaemia 52.59 30.89 17 5320 543 1740901
Hyperbilirubinaemia 52.57 30.89 25 5312 2262 1739182
Treatment failure 52.38 30.89 31 5306 4370 1737074
Blood lactate dehydrogenase increased 52.06 30.89 29 5308 3646 1737798
Dyspepsia 51.33 30.89 32 5305 4953 1736491
Arterial occlusive disease 50.80 30.89 18 5319 764 1740680
Necrosis 50.67 30.89 19 5318 949 1740495
Leukopenia 48.62 30.89 38 5299 8442 1733002
Ischaemia 48.48 30.89 18 5319 874 1740570
Pulmonary oedema 47.79 30.89 34 5303 6552 1734892
Gene mutation 47.62 30.89 12 5325 151 1741293
Transient ischaemic attack 47.43 30.89 30 5307 4761 1736683
Facial paralysis 47.29 30.89 22 5315 1894 1739550
C-reactive protein increased 46.48 30.89 32 5305 5853 1735591
Neck pain 46.15 30.89 26 5311 3340 1738104
Gastrooesophageal reflux disease 45.75 30.89 29 5308 4618 1736826
Haematocrit decreased 45.43 30.89 28 5309 4245 1737199
General physical health deterioration 45.26 30.89 44 5293 13074 1728370
Skin ulcer 45.03 30.89 24 5313 2764 1738680
Vertigo 44.60 30.89 28 5309 4385 1737059
Infarction 44.36 30.89 16 5321 715 1740729
Cytopenia 44.05 30.89 17 5320 919 1740525
Inappropriate schedule of product administration 44.01 30.89 34 5303 7425 1734019
Blood cholesterol increased 43.19 30.89 24 5313 3002 1738442
Blood alkaline phosphatase increased 42.80 30.89 29 5308 5166 1736278
Exposure via father 42.24 30.89 10 5327 95 1741349
Renal impairment 41.91 30.89 41 5296 12273 1729171
Blast cell crisis 41.37 30.89 9 5328 56 1741388
Red blood cell count decreased 41.35 30.89 25 5312 3661 1737783
Labelled drug-food interaction medication error 41.24 30.89 8 5329 25 1741419
Jaundice 41.02 30.89 30 5307 6032 1735412
Cardiac disorder 40.95 30.89 33 5304 7658 1733786
Weight increased 40.88 30.89 39 5298 11318 1730126
Insomnia 40.76 30.89 46 5291 16230 1725214
Acquired gene mutation 40.75 30.89 11 5326 184 1741260
Blast cells present 40.58 30.89 9 5328 62 1741382
Blood urea increased 40.49 30.89 27 5310 4684 1736760
Visual impairment 40.34 30.89 30 5307 6188 1735256
Influenza 40.26 30.89 31 5306 6736 1734708
Cardiac arrest 39.85 30.89 45 5292 15885 1725559
Blood uric acid increased 39.35 30.89 16 5321 993 1740451
Pancreatitis acute 38.98 30.89 25 5312 4062 1737382
Cerebral artery stenosis 38.56 30.89 9 5328 80 1741364
Cardiovascular disorder 38.47 30.89 21 5316 2536 1738908
Depression 38.19 30.89 45 5292 16624 1724820
Hyperhidrosis 37.76 30.89 39 5298 12449 1728995
Arteritis 37.16 30.89 9 5328 95 1741349
Vision blurred 36.30 30.89 32 5305 8391 1733053
Cardiac failure congestive 36.27 30.89 42 5295 15228 1726216
Tricuspid valve incompetence 36.09 30.89 16 5321 1230 1740214
Skin disorder 36.00 30.89 19 5318 2145 1739299
Chronic obstructive pulmonary disease 34.81 30.89 27 5310 5926 1735518
Hepatotoxicity 34.81 30.89 21 5316 3063 1738381
Cardiomegaly 34.65 30.89 19 5318 2315 1739129
Memory impairment 34.22 30.89 28 5309 6635 1734809
Sepsis 34.21 30.89 46 5291 19392 1722052
Ischaemic cardiomyopathy 34.10 30.89 15 5322 1132 1740312
Blister 34.08 30.89 23 5314 4069 1737375
Philadelphia chromosome positive 33.99 30.89 7 5330 32 1741412
Prostate cancer 33.82 30.89 24 5313 4602 1736842
Tumour lysis syndrome 33.82 30.89 17 5320 1734 1739710
Peripheral swelling 33.79 30.89 30 5307 7941 1733503
Blood phosphorus decreased 33.66 30.89 12 5325 518 1740926
Flatulence 33.17 30.89 20 5317 2914 1738530
Stent placement 32.91 30.89 14 5323 974 1740470
Pericarditis 32.88 30.89 16 5321 1522 1739922
Type 2 diabetes mellitus 32.69 30.89 17 5320 1861 1739583
Aphasia 32.58 30.89 21 5316 3440 1738004
Hepatic enzyme increased 32.29 30.89 27 5310 6594 1734850
Chloroma 32.17 30.89 8 5329 95 1741349
Leukaemia recurrent 31.88 30.89 10 5327 289 1741155
Hemiparesis 31.85 30.89 19 5318 2715 1738729
Muscular weakness 30.96 30.89 32 5305 10217 1731227

Pharmacologic Action:

SourceCodeDescription
ATC L01XE08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000175076 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Gastrectomy contraindication 53442002
Diabetes mellitus contraindication 73211009 DOID:9351
Pancreatitis contraindication 75694006 DOID:4989
Hyperglycemia contraindication 80394007 DOID:4195
Hyponatremia contraindication 89627008
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Elevated Serum Lipase contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.89 acidic
pKa2 6.03 Basic
pKa3 3.97 Basic
pKa4 2.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.44 CHEMBL CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5.32 PDSP
Fibroblast growth factor receptor 2 Kinase Ki 5.14 PDSP
Fibroblast growth factor receptor 1 Kinase Ki 5.10 PDSP
Tyrosine-protein kinase JAK2 Kinase Ki 5.07 PDSP
Mitogen-activated protein kinase 10 Kinase Kd 5.70 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 4.40 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8.39 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.24 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.72 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.13 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 6.14 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.96 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 6.23 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.05 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.49 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 7.07 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.68 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 7.43 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 6.64 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.17 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.33 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.44 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.41 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 7.80 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 5.06 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 7.77 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.19 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.15 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 7 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.72 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 6.48 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.89 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.52 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 6.04 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 7.59 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.35 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.30 CHEMBL
Angiopoietin-1 receptor Kinase Kd 6 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.30 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 6.35 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.77 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.80 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.35 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.22 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.06 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.96 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.33 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 6.19 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 7.44 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 5.26 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 6 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 6.65 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 7 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.38 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.53 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.83 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.34 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.34 CHEMBL
Insulin receptor Kinase Ki 5.39 PDSP
Bcr/Abl fusion protein Kinase IC50 9.48 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.33 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.10 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.10 CHEMBL

External reference:

IDSource
4026964 VUID
N0000176124 NUI
C1721377 UMLSCUI
D06413 KEGG_DRUG
5JHU0N1R6K UNII
923288-90-8 SECONDARY_CAS_RN
428468009 SNOMEDCT_US
662281 RXNORM
d07057 MMSL
427941004 SNOMEDCT_US
4026964 VANDF
012401 NDDF
CHEMBL255863 ChEMBL_ID
8654 INN_ID
NIL PDB_CHEM_ID
DB04868 DRUGBANK_ID
CHEBI:52172 CHEBI
CHEMBL1201740 ChEMBL_ID
C498826 MESH_SUPPLEMENTAL_RECORD_UI
644241 PUBCHEM_CID
5697 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0526 CAPSULE 200 mg ORAL NDA 19 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0592 CAPSULE 150 mg ORAL NDA 19 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0951 CAPSULE 50 mg ORAL NDA 19 sections